Justices Urged To Pass On Orexigen Disclosure Dispute
By Rachel Graf ( April 5, 2019, 5:51 PM EDT) -- An investor in now-bankrupt Orexigen told the U.S. Supreme Court on Friday there's no need to review the Ninth Circuit's ruling that the biotechnology company had a duty to warn investors when new information about a drug conflicted with prior findings that were accurate when disclosed....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.